Examine Delivering Drugs By Inhalation and Emerging Therapeutic Opportunities With This Essential and Comprehensive Report
Posted on: Wednesday, 1 October 2008, 06:00 CDT
Research and Markets (http://www.researchandmarkets.com/research/45fffb/delivering_drugs_b) has announced the addition of the "Delivering Drugs by Inhalation - Emerging Therapeutic Opportunities" report to their offering.
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions - aliments that require frequent drug administration for a protracted period of time. The role of device design and development in defining and driving emerging opportunities in this sector cannot be overstated. Nebulizers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs) have each found a niche in the quest for optimal treatment and convenient use. While nebulizers have evolved relatively independently of the drug formulations they deliver, the current generation of MDIs and DPIs have been developed or tailored for the specific pharmaceutical being delivered, resulting in improved performance. Several of the emerging drug products covered in this report will have a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated.
Market Data The study presents qualitative and quantitative data and information on key market measures and benchmarks: -Inhaled Drug Delivery Market Segment size and AGR -Device-Pharma Alliance Activity and Deal Structure -Inhaled Drug Economic Factors -Strategic Positioning Factors -Industry Structure & Competitive Landscape -Combination Product Design Parameters -Third-party Stakeholders Market Participant Profiles -Market Dynamics & Sensitivities -Competitive Risks -Proprietary Technology Assessment -Self-Administration Compliance Factors -Technology Risk Factors -Regulatory Risk Factors Forecasts and Projections cover the Period 2008-2011 Key Topics Covered: Executive Summary Inhaled Drug Delivery Market Dynamics - Portrait of an Evolving Market - Established Therapeutic Targets - Emerging Therapies - Demographics and Growth - Competing Technologies - Market Drivers - Factors Limiting Growth Inhalation Technology - Drug Formulations - Inhaler Designs - Dry Powder Inhalers - Metered Dose Inhalers - Nebulizers - Performance Factors - Bioavailability - Dose Reproducibility - Active Compound Stability - Commercial Devices - Development-Stage Devices - Combination Products - Emerging Device Technologies Inhaled Drugs - Development-stage Product Candidates - Anaphylaxis - Cardiovascular Medicine - Hereditary Diseases - Immunology - Infectious Diseases - Metabolic - Growth Deficiencies - Osteoporosis - Neurology - Antipsychotics - Migraine - Parkinson's - Oncology - Pain Management - Respiratory - Sexual Health Market Factors - Device Packaging - Regulatory Issues - Patient Compliance - The Role of CMOs/CSOs - Healthcare Economics Company Profiles - Detailed Profiles of Market Sector Participants
For more information visit http://www.researchandmarkets.com/research/45fffb/delivering_drugs_b
Source: Business Wire
Related Articles
- U.S. Market for Female Sterilization Devices to Grow 36% in 2009
- Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
- Research and Markets: Opioid Antagonists Are the Most Prevalent Drug Class in Late-Stage Development for the Alcohol Dependence Pipeline Which Include Two Reformulations of Naltrexone
- Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double By 2016
- Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices
- Drying Up Drug Supply: Change in Asthma Inhalers Could Make Them Hard to Find
- The Personalized Medicine Market Aims to Match the Most Appropriate Drug to the Right Person
- The U.S. Food and Drug Administration Will Use GeneGo's MetaCore for 'OMIC's' Research and Reviewing of Genomics Data
- White-Coat Effect is Virtually Eliminated Using a Non-Drug Hypertension Treatment Device
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds